NMTR — 9 Meters Biopharma Share Price
Last Trade - 00:00- $258.91m
- $220.42m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.07 | 1.88 | n/a | n/a | n/a | n/a | 8.33 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
9 Meters Biopharma, Inc., formerly Innovate Biopharmaceuticals, Inc., is a gastrointestinal platform company. The Company is focused on developing treatments for patients with rare disorders and unmet needs. Its pipeline includes drug candidates for short bowel syndrome and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis.
Directors
- Mark Sirgo (67)
- John Temperato (56)
- Edward Sitar CFO (60)
- Michael Constantino (58)
- Lorin Johnson (68)
- Michael Rice (56)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- November 9th, 2010
- Public Since
- July 8th, 2016
- No. of Shareholders
- 294
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 251,372,296
- Address
- 8480 Honeycutt Rd Ste 120, RALEIGH, 27615-2261
- Web
- http://www.innovatebiopharma.com/
- Phone
- +1 9192751933
- Contact
- Corey Davis
- Auditors
- Mayer Hoffman & McCann P.C.
Latest News for NMTR
Upcoming events for NMTR
Similar to NMTR
180 LIFE SCIENCES ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
ADITXT ORD
NASDAQ Capital Market
FAQ
As of Today at 19:53 UTC, shares in 9 Meters Biopharma are trading at $1.03. This share price information is delayed by 15 minutes.
Shares in 9 Meters Biopharma last closed at $1.03 and the price had moved by +84.65% over the past 365 days. In terms of relative price strength the 9 Meters Biopharma share price has outperformed the S&P500 Index by +40.09% over the past year.
The overall consensus recommendation for 9 Meters Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
9 Meters Biopharma does not currently pay a dividend.
9 Meters Biopharma does not currently pay a dividend.
9 Meters Biopharma does not currently pay a dividend.
To buy shares in 9 Meters Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.03, shares in 9 Meters Biopharma had a market capitalisation of $258.91m.
Here are the trading details for 9 Meters Biopharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NMTR
Shares are classified based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
9 Meters Biopharma does not currently have a style classification.
The analyst consensus target price for shares in 9 Meters Biopharma is $4.36. That is 323.3% above the last closing price of $1.03.
Analysts covering 9 Meters Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.13 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 9 Meters Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -53.34%.
As of the last closing price of $1.03, shares in 9 Meters Biopharma were trading -15.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for 9 Meters Biopharma.
9 Meters Biopharma's management team is headed by:
- Mark Sirgo -
- John Temperato -
- Edward Sitar - CFO
- Michael Constantino -
- Lorin Johnson -
- Michael Rice -
We do not have data on 9 Meters Biopharma's shareholders